Valion Bio begins FDA-backed study of Entolimod™ for radiation injury with $7M NIAID funding

Valion Bio has started a government-funded study to test Entolimod™ for preserving gastrointestinal tissue in partial-body acute radiation syndrome, a condition with no current effective treatments. The $7 million NIAID-backed study uses an FDA-accepted protocol and aims to support a Biologics License Application under the FDA's Animal Rule. Success would make Entolimod™ the only countermeasure protecting both hematopoietic and gastrointestinal tissues, addressing a critical gap in radiation injury treatment. The program is fully funded and supported by the U.S. government, reducing financial and regulatory risks for Valion Bio.